SG Americas Securities LLC Invests $139,000 in Quanterix Co. (NASDAQ:QTRX)

SG Americas Securities LLC bought a new position in shares of Quanterix Co. (NASDAQ:QTRX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 10,722 shares of the company’s stock, valued at approximately $139,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Comerica Bank raised its holdings in Quanterix by 44,205.6% during the first quarter. Comerica Bank now owns 7,975 shares of the company’s stock worth $188,000 after purchasing an additional 7,957 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in Quanterix in the second quarter valued at $140,000. Janney Capital Management LLC acquired a new position in Quanterix in the first quarter valued at $259,000. Hsbc Holdings PLC increased its position in shares of Quanterix by 34.7% during the second quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock worth $164,000 after purchasing an additional 3,279 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Quanterix by 22.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 12,844 shares of the company’s stock valued at $303,000 after purchasing an additional 2,340 shares during the last quarter. Hedge funds and other institutional investors own 86.48% of the company’s stock.

Quanterix Stock Performance

Shares of Quanterix stock opened at $12.47 on Friday. Quanterix Co. has a one year low of $10.50 and a one year high of $29.70. The company has a market cap of $477.23 million, a P/E ratio of -12.99 and a beta of 1.36. The firm has a fifty day moving average of $12.72 and a two-hundred day moving average of $14.32.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Quanterix had a negative return on equity of 11.52% and a negative net margin of 30.71%. The firm had revenue of $34.38 million for the quarter, compared to analysts’ expectations of $34.19 million. During the same period in the prior year, the company earned ($0.16) earnings per share. As a group, equities analysts predict that Quanterix Co. will post -0.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

QTRX has been the topic of several research analyst reports. The Goldman Sachs Group reduced their price objective on Quanterix from $35.00 to $24.00 and set a “buy” rating for the company in a research note on Tuesday, July 9th. Scotiabank lowered their price objective on shares of Quanterix from $32.00 to $28.00 and set a “sector outperform” rating on the stock in a research report on Monday, August 12th. Finally, TD Cowen dropped their price objective on shares of Quanterix from $17.00 to $15.00 and set a “hold” rating on the stock in a research note on Friday, August 9th.

Insider Activity at Quanterix

In other Quanterix news, Director David R. Walt acquired 47,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was purchased at an average price of $13.29 per share, for a total transaction of $624,630.00. Following the completion of the transaction, the director now owns 1,487,342 shares of the company’s stock, valued at $19,766,775.18. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 6.90% of the company’s stock.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.